Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Liminatus Pharma Inc. (LIMN) had Return on Tangible Equity of 110.79% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.82M |
|
-- |
|
-- |
|
$0.70M |
|
$-0.70M |
|
$-1.12M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-0.70M |
|
$-0.70M |
|
27.01M |
|
27.01M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$1.20M |
|
$0.01M |
|
$0.14M |
|
$1.34M |
|
$2.86M |
|
-- |
|
$0.12M |
|
$2.99M |
|
$-1.65M |
|
$-1.65M |
|
$-1.65M |
|
27.07M |
|
| Cash Flow Statement Financials | |
$-9.58M |
|
$-0.79M |
|
$11.03M |
|
$0.06M |
|
$0.72M |
|
$0.67M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.42 |
|
-- |
|
-- |
|
-- |
|
-0.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
110.79% |
|
|
Return on Tangible Equity |
110.79% |
-135.83% |
|
110.79% |
|
$-0.06 |
|
$-0.36 |
|
$-0.35 |
|